Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Eikon Therapeutics Inc (EIKN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.84-8.61%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for EIKN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient cash to fund operations into second half of 2027 | Eikon Therapeutics aims to fund operations into the second half of 2027 with $596M cash. | Intact | cash falls below level needed to fund operations into second half of 2027 | Cash and cash equivalents: $143.013M FY2026-Q2; GAAP. Published target: cash sufficient to fund operations into 2H 2027. Target period ends 2027-06-30; this observation covers 2026-Q2. Date unavailable143,013,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage healthcare business, with a multi-year thesis tied to advancing its oncology pipeline. The thesis is in a watch state: management has made progress on trial milestones, but recent financial performance is weak and confidence in the evidence is low.
The evidence snapshot provides no valuation measures or direct account of market expectations, so it is not possible to describe whether EIKN is cheap, fair, or expensive versus peers. The recent downward price reaction and weak results point to pressure on expectations, but do not establish what the market already assumes.
Near term, consecutive earnings misses and an elevated risk of another miss make results and guidance important. The company reported promising response and disease-control rates in one trial cohort and progress in a registrational trial, while cash declined between March and June; management still reiterated a runway into the second half of 2027. A litigation filing adds risk, while the stronger healthcare sector backdrop is a potential support.
The multi-year thesis hinges on whether clinical progress can continue and whether the company can fund operations through its stated runway. Near term, a guidance cut or further weakening in jobs data would add pressure; continued earnings strength and higher guidance from sector bellwethers could support healthcare-sector momentum. The snapshot does not provide enough detail to assess the litigation’s potential impact.
Over the next one to three years, EIKN remains a high-risk pipeline story with some clinical progress but weak financial performance and limited evidence for assessing valuation. The thesis depends on continued trial execution, funding runway, and near-term results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.” “Eikon expects its current cash, cash equivalents, and marketable securities, to fund operations into the second half of 2027.”
Delivery assessment Nov 5, 2026Manage net income losses to sustain operations | A supporting condition in Eikon Therapeutics Inc's published investment case. The stated target is net income losses no worse than -$82.9M next quarter. | Under Pressure | net income losses worsen beyond -$82.9M next quarter | Net income: $-88.409M FY2026-Q2; GAAP. Published target: net income losses no worse than -$82.9M next quarter. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 13, 2026-88,409,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “General and Administrative (“G&A”) Expenses: G&A expenses were $17.9 million for the three months ended June 30, 2026, compared to $40.5 million for the three months ended June 30, 2025, a decrease of $22.5 million, or 56%.” “Net Loss : Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026, compared to $105.2 million for the prior-year period.” Net income was $-88.409 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Control operating losses to manage cash burn | Operating losses are managed but increased from -$71.4M to -$87.3M in 2026-Q1. | Under Pressure | operating losses worsen beyond -$87.3M next quarter | Operating income: $-93.394M FY2026-Q2; GAAP. Published target: operating losses no worse than -$87.3M next quarter. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 13, 2026-93,394,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “General and Administrative (“G&A”) Expenses: G&A expenses were $17.9 million for the three months ended June 30, 2026, compared to $40.5 million for the three months ended June 30, 2025, a decrease of $22.5 million, or 56%.” “Net Loss : Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026, compared to $105.2 million for the prior-year period.” Net income was $-88.409 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Advance product development with clinical progress | The company advances product development with six abstracts at ASCO 2026. | Intact | lack of clinical progress or negative trial results | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.66 → $-7.28 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.66 | Unavailable | 5 / 0 |
| 2026-07-25 | $-6.66 | Unavailable | 5 / 0 |
| 2026-07-26 | $-6.66 | Unavailable | 5 / 0 |
| 2026-07-27 | $-6.19 | $0 | 5 / 4 |
| 2026-07-28 | $-6.66 | Unavailable | 5 / 0 |
| 2026-07-29 | $-6.66 | Unavailable | 5 / 0 |
| 2026-07-30 | $-6.19 | $0 | 5 / 4 |
| 2026-07-31 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-01 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-02 | $-6.19 | $0 | 5 / 4 |
| 2026-08-03 | $-6.19 | $0 | 5 / 4 |
| 2026-08-04 | $-6.19 | $0 | 5 / 4 |
| 2026-08-05 | $-6.19 | $0 | 5 / 4 |
| 2026-08-06 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-07 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-08 | $-6.19 | $0 | 5 / 4 |
| 2026-08-09 | $-6.19 | $0 | 5 / 4 |
| 2026-08-10 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-11 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-12 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-13 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-14 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-15 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-16 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-17 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-18 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-19 | $-6.66 | Unavailable | 5 / 0 |
| 2026-08-20 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-21 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-22 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-23 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-24 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-25 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-26 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-27 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-28 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-29 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-30 | $-6.79 | Unavailable | 5 / 0 |
| 2026-08-31 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-01 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-02 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-03 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-04 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-05 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-06 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-07 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-08 | $-6.79 | Unavailable | 5 / 0 |
| 2026-09-09 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-10 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-11 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-12 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-13 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-14 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-15 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-16 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-17 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-18 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-19 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-20 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-21 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-22 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-23 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-24 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-25 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-26 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-27 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-28 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-29 | $-7.08 | Unavailable | 5 / 0 |
| 2026-09-30 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-01 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-02 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-03 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-04 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-05 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-06 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-07 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-08 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-09 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-10 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-11 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-12 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-13 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-14 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-15 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-16 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-17 | $-7.08 | Unavailable | 5 / 0 |
| 2026-10-18 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-19 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-20 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-21 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-22 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-23 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-24 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-25 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-26 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-27 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-28 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-29 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-30 | $-7.28 | Unavailable | 6 / 0 |
| 2026-10-31 | $-7.28 | Unavailable | 6 / 0 |
| 2026-11-01 | $-7.28 | Unavailable | 6 / 0 |
| 2026-11-02 | $-7.28 | Unavailable | 6 / 0 |
| 2026-11-03 | $-7.28 | Unavailable | 6 / 0 |
| 2026-11-04 | $-7.28 | Unavailable | 6 / 0 |
| 2026-11-05 | $-7.28 | Unavailable | 6 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.